Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometry

Patent expiration of first-generation biologics and the high cost of innovative biologics are 2 drivers for the development of biosimilar products. There are, however, technical challenges to the production of exact copies of such large molecules. In this study, we performed a head-to-head compariso...

Descripción completa

Detalles Bibliográficos
Autores principales: Griaud, François, Winter, Andrej, Denefeld, Blandine, Lang, Manuel, Hensinger, Héloïse, Straube, Frank, Sackewitz, Mirko, Berg, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680803/
https://www.ncbi.nlm.nih.gov/pubmed/28846476
http://dx.doi.org/10.1080/19420862.2017.1366395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680803/
https://www.ncbi.nlm.nih.gov/pubmed/28846476
http://dx.doi.org/10.1080/19420862.2017.1366395

Ejemplares similares